Pharma BD Deal Intelligence
Biocon Biologics to acquire Viatris' global biosimilars assets for up to $3.335 billion in stock and cash, creating a unique fully vertically integrated global…
Biocon Biologics acquired Viatris biosimilars business for $3B.
Dec 6, 2025: Viatris agreed to monetize its convertible preferred equity stake in Biocon Biologics Limited, selling to Biocon Limited for total consideration…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Biocon Biologics acquired Viatris biosimilars business for $3B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biocon Biologics Ltd. / Viatris Biosimilars Business (this deal) | 2022 | $3.0B | 72 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Johnson & Johnson / Abiomed Inc. | 2022 | $16.6B | 74 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2022 deals